Increased hepcidin-25 and erythropoietin responsiveness in patients with cardio-renal anemia syndrome

Future Cardiology

Volumn 6, Issue 6, 2010, Pages 769-771

  Kato, Akihiko ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

chronic heart failure; chronic kidney disease; erythropoietin responsiveness; hepcidin 25; inflammation

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN; HEPCIDIN 25; INTERLEUKIN 6; PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; CARDIO RENAL ANEMIA SYNDROME; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; HEART FAILURE; HUMAN; INFLAMMATION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE; TREATMENT RESPONSE;

ANEMIA; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CYSTATIN C; ERYTHROPOIETIN, RECOMBINANT; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; MASS SCREENING; STATISTICS AS TOPIC; TREATMENT OUTCOME;

EID: 78650217744     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.10.97     Document Type: Article

References (14)

1. Dallalio G, Law E, Means RT: Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood 107, 2702-2704 (2006).
2. Ashby DR, Gale DP, Busbridge M et al.: Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 75, 976-981 (2009).
3. van der Putten K, Jie KE, van den Broek D et al.: Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/ chronic heart failure patients. Eur. J. Heart Fail. 12(9), 943-950 (2010).
4. Anker SD, Comin Colet J, Filippatos G et al.: Ferric carboxymaltose in patients with heart failure and iron defciency. N. Engl. J. Med. 362, 2636-2648 (2009).
5. Srai SK, Chung B, Marks J et al.: Erythropoietin regulates intestinal iron absorption in a rat model of chronic renal failure. Kidney Int. 78(7), 660-667 (2010).
6. Zaritsky J, Young B, Wang HJ et al.: Hepcidin - a potential novel biomarker for iron status in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 4, 1051-1056 (2009).
7. Peters HPE, Laarakkers CMM, Swinkels DW et al.: Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular fltration rate. Nephrol. Dial. Transplant. 25, 848-853 (2010).
8. Kato A, Tsuji T, Luo J et al.: Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am. J. Nephrol. 28, 115-121 (2008).
9. Ford BA, Eby CS, Scott MG et al.: Intra-individual variability in serum hepcidin preclude its use as a marker of iron status in hemodialysis patients. Kidney Int. doi: 10.1038/ki.2010.254 (2010) (Epub ahead of print).
10. Babitt JL, Huang FW, Xia Y et al.: Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J. Clin. Invest. 117, 1933-1939 (2007).
11. Yu PB, Hong CC, Sachidanandan C et al.: Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat. Chem. Biol. 4, 33-41 (2008).
12. Song SN, Tomosugi N, Kawabata H et al.: Downregulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of infammation in multicentric Castleman's disease (MCD). Blood 116(18), 3627-3634 (2010).
13. Fatih N, Camberlein E, Island ML et al.: Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form. J. Mol. Med. 88, 477-486 (2010).
14. Pfeffer MA, Burdmann EA, Chen CY et al.: A trial of darbepoetin-a in Type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019-2032 (2009).